Calò Pierluigi, Pianton Nicolas, Basle Alexandre, Vasiljevic Alexandre, Barritault Marc, Beuriat Pierre Aurélien, Faure-Conter Cécile, Leblond Pierre
Department of Pediatric Oncology, Institute of Pediatric Hematology and Oncology, 69008 Lyon, France.
Department of Ophtalmology, Edouard-Herriot Hospital, 69003 Lyon, France.
Cancers (Basel). 2023 Feb 7;15(4):1036. doi: 10.3390/cancers15041036.
This is a retrospective study conducted on patients with OPG, aged less than 19 years, treated with bevacizumab as a single agent, since 2010 at IHOPe (Institute of Pediatric Hematology and Oncology). Efficacy of the treatment was evaluated on the tumor response rate on MRI with a centralized review basing upon RAPNO criteria and with visual assessment basing upon a 0.2 log change in the logMAR scale. Thirty-one patients with OPG have been included. From a radiological point of view, best anytime responses were: 1 major response, 6 partial responses, 7 minor responses and 14 stable diseases; achieving disease control in 28 (96%) out of 29 patients. Ophthalmological response was evaluated in 25 patients and disease control was achieved in 22 (88%) out of 25, with 14 steady states and 8 significant improvements. Among patients treated with chemotherapy after the bevacizumab course, nine relapsed and have been retreated with objective responses. Bevacizumab used as single agent seems effective in children and adolescents with OPG. Our work paves the way for a phase II study in which bevacizumab alone could be used as frontline therapy.
这是一项回顾性研究，自2010年起在IHOPe（儿科血液学和肿瘤学研究所）对年龄小于19岁、接受贝伐单抗单药治疗的成视网膜细胞瘤（OPG）患者开展。基于RAPNO标准通过集中审查在MRI上的肿瘤反应率以及基于logMAR量表中0.2对数变化的视觉评估来评估治疗效果。纳入了31例OPG患者。从放射学角度来看，最佳任何时间反应为：1例主要反应、6例部分反应、7例轻微反应和14例病情稳定；29例患者中有28例（96%）实现疾病控制。对25例患者评估了眼科反应，25例中有22例（88%）实现疾病控制，其中14例病情稳定，8例有显著改善。在贝伐单抗疗程后接受化疗的患者中，9例复发并再次接受治疗且有客观反应。贝伐单抗单药治疗似乎对患有OPG的儿童和青少年有效。我们的工作为一项II期研究铺平了道路，在该研究中贝伐单抗可单独用作一线治疗。
